4SC AG (FSCGF.PK) Wednesday said it has been granted a key patent for its lead anti-cancer compound resminostat in Japan. The patent covers the composition of matter of resminostat, pharmaceutical compositions comprising resminostat and its therapeutic use in cancer and other therapeutic areas.
The company is engaged in the discovery and development of targeted small molecule drugs for autoimmune diseases and cancer. In April, 4SC granted an exclusive license to Yakult Honsha for the development and commercialization of resminostat in Japan. Hepatocellular carcinoma, the most common type of liver cancer, has a particularly high incidence in Japan.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.